Disease severity and symptoms among patients receiving monotherapy for COPD

Primary Care Respiratory Journal

Volumn 20, Issue 1, 2011, Pages 46-53

  Dransfield, Mark T ^a   Bailey, William ^a   Crater, Glenn ^b   Emmett, Amanda ^b   O'Dell, Dianne M ^b   Yawn, Barbara ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b GLAXOSMITHKLINE   (United States)

^c OLMSTED MEDICAL CENTER   (United States)

Author keywords

COPD; Disease severity; Long acting bronchodilator; Monotherapy; Quality of life; Spirometry; Symptoms

Indexed keywords

BRONCHODILATING AGENT; FORMOTEROL; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERTENSION; HYPOGLYCEMIA; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PETECHIA; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SPIROMETRY; SYMPTOMATOLOGY; TOOTH FRACTURE; TREMOR;

EID: 80053065296     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2010.00059     Document Type: Article

References (34)

1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. MMWR Surveill Summ 2002;51(6):1-16.
2. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J 2007;30(5):993-1013. http://dx.doi.org/10.1183/09031936.00082507
3. Yawn B, Mannino D, Littlejohn T, et al. Prevalence of COPD among symptomatic patients in a primary care setting. Curr Med Res Opin 2009;25(11):2671-7.
4. National Heart, Lung and Blood Institute Chartbook, US Department of Health and Human Services, National Institute of Heath; 2004.
5. American LA. Trends in chronic bronchitis and emphysema: morbidity and mortality [Internet]. [cited 2010 Mar 29];Available from: http://www.lungusa.org
6. Price D, Crockett A, Arne M, et al. Spirometry in primary care case-identification, diagnosis and management of COPD. Prim Care Resp J 2009;18(3):216-23. http://dx.doi.org/10.4104/pcrj.2009.00055
7. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004;1(2):303-12.
8. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006;28(6):1245-1257. http://dx.doi.org/10.1183/09031936.00133805
9. Yawn BP, Kaplan A. Co-morbidities in people with COPD: a result of multiple diseases, or multiple manifestations of smoking and reactive inflammation? Prim Care Resp J 2008;17(4):199-205. http://dx.doi.org/10.3132/pcrj.2008.00021
10. Yawn BP, Wollan PC. Knowledge and attitudes of family physicians coming to COPD continuing medical education. Int J Chron Obstruct Pulmon Dis 2008;3(2):311-17.
11. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-535. http://dx.doi.org/ 10.1164/rccm.200703-456SO
12. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54(7):581e6.
13. Schumemann JH, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic Respiratory Questionnaire (CRQ). J COPD 2005;2:81-9. http://dx.doi.org/10.1081/COPD-200050651
14. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85(6):751-8. http://dx.doi.org/10.1378/chest.85.6.751
15. Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009;180(6):506-12. http://dx.doi.org/10.1164/rccm.200812-1873OC
16. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31(2):416-69. http://dx.doi.org/10.1183/09031936.00099306
17. Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. Respir Med 1999;93(3):173-179. http://dx.doi.org/10.1016/S0954-6111(99)90004-5
18. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57(10):847-52. http://dx.doi.org/10.1136/thorax.57.10.847
19. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000;117(3):662-71. http://dx.doi.org/10.1378/chest.117.3.662
20. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Resp J 2006;15(6):346-53. http://dx.doi.org/10.1016/j.pcrj.2006.08.009
21. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008;177(4):396-401. http://dx.doi.org/10.1164/rccm.200708-1290OC
22. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-46. http://dx.doi.org/10.1183/09031936.04.00014304
23. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350(10):1005-12. http://dx.doi.org/10.1056/NEJMoa021322
24. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34(3):648-54. http://dx.doi.org/10.1183/09031936.00102509
25. Han MK, Bartholmai B, Liu LX, Murray S, Curtis JL, Sciurba FC. Clinical significance of radiologic characterizations in COPD. COPD 2009;6(6):459-67.
26. National Clinical Guideline Centre. (2010) Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care London: National Clinical Guideline Centre. www.nice.org.uk/CG101
27. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007;14 Suppl B:5B-32B.
28. Buffels J, Degryse J, Liistro G. Diagnostic certainty, co-morbidity and medication in a primary care population with presumed airway obstruction: the DIDASCO2 study. Prim Care Resp J 2009;18(1):34-40.
29. Knuiman MW, James AL, Divitini ML, Ryan G, Bartholomew HC, Musk AW. Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study. Ann Epidemiol 1999;9(5):297-306. http://dx.doi.org/10.1016/S1047- 2797(98)00066-0
30. Eisner MD, Blanc PD, Yelin EH, Katz PP, Sanchez G, Iribarren C, Omachi TA. Influence of anxiety on health outcomes in COPD. Thorax 2010;65(3):229-34. http://dx.doi.org/10.1136/thx.2009.126201
31. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26. http://dx.doi.org/10.1378/chest.129.1.15
32. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58(8):647-8. http://dx.doi.org/10.1136/thorax.58.8.659
33. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124(3):834-843. http://dx.doi.org/ 10.1378/chest.124.3.834
34. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-1554. http://dx.doi.org/ 10.1056/NEJMoa0805800